# Sacituzumab govitecan

A multi-agent workflow under investigator direction carried a large electronic health record study from cohort construction and executable statistics through data-quality checks, literature retrieval and reporting, using sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) orders in breast cancer as the clinical case. From 4.95 million patients, 106 had orders for both drugs, 73 with T-DXd first and 33 with SG first; median second-drug record spans were 63 and 49 days, a median difference of −14 days (95% CI, −41 to 21), descriptive and unadjusted.

A multi-agent workflow under investigator direction carried a large electronic health record study from cohort construction and executable statistics through data-quality checks, literature retrieval and reporting, using sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) orders in breast cancer as the clinical case. From 4.95 million patients, 106 had orders for both drugs, 73 with T-DXd first and 33 with SG first; median second-drug record spans were 63 and 49 days, a median difference of −14 days (95% CI, −41 to 21), descriptive and unadjusted.

This review indicates that TROP2-directed antibody-drug conjugates (ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings, and that although sacituzumab govitecan and datopotamab deruxtecan share TROP2 targeting and topoisomerase I inhibition, their safety profiles differ—sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis—differences attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake, with corresponding agent-specific, proactive and increasingly individualized preve

This review indicates that TROP2-directed antibody-drug conjugates (ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings, and that although sacituzumab govitecan and datopotamab deruxtecan share TROP2 targeting and topoisomerase I inhibition, their safety profiles differ—sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis—differences attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake, with corresponding agent-specific, proactive and increasingly individualized preve